GlassScriptPhysician profile
James B Butler
NPI 1508802935
$6,186.71
in general payments reported to CMS, 2019-2025
39 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,876 · 2020: $1,024 · 2021: $1,811 · 2022: $638 · 2023: $228 · 2024: $280 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,385.22 | 2019-2025 | |
| Abbvie INC. | $642.36 | 2021-2024 | Botox |
| Biogen, INC. | $450.95 | 2019-2021 | |
| Ucb, INC. | $384.42 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $322.81 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $318.73 | 2019-2021 | |
| Lilly USA, LLC | $253.93 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $238.24 | 2019-2021 | |
| Genzyme Corporation | $204.60 | 2019-2022 | |
| Genentech USA, INC. | $167.65 | 2019 | |
| Amneal Pharmaceuticals LLC | $156.08 | 2019-2024 | Rytary |
| Sk Life Science, INC. | $154.80 | 2020-2021 | |
| Amgen INC. | $148.14 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $147.64 | 2021 | |
| Adamas Pharmaceuticals, INC. | $107.89 | 2019-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $99.27 | 2019-2021 | |
| Emd Serono, INC. | $96.01 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $94.04 | 2019-2021 | |
| Celgene Corporation | $93.98 | 2021-2022 | |
| Allergan, INC. | $87.15 | 2019-2021 | |
| Eisai INC. | $80.70 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $63.23 | 2019-2020 | |
| Acorda Therapeutics, INC | $61.50 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.38 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.26 | 2020 | |
| Neurocrine Biosciences, INC. | $43.90 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $38.18 | 2019-2021 | |
| Mdd US Operations, LLC | $31.89 | 2019 | |
| Lundbeck LLC | $24.84 | 2019 | |
| Shire North American Group INC | $22.83 | 2019 | |
| Horizon Therapeutics Plc | $22.25 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.80 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2021 | |
| Promius Pharma LLC | $18.92 | 2019 | |
| Banner Life Sciences, LLC | $17.37 | 2021 | |
| Neos Therapeutics, LP | $17.14 | 2020 | |
| Alnylam Pharmaceuticals INC. | $17.12 | 2019 | |
| Currax Pharmaceuticals LLC | $14.48 | 2020 | |
| Grifols USA, LLC | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.